medmix AG (MEDX) Fair Value & Analysis
Industrials · CH · Market cap CHF 368M
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from CHF 5.23 to CHF 3.30 (−36.9%) since Jun 23, 2026. Share price −12.6% over the past month.
Price vs Fair Value (12 months)
12‑month range CHF 8.23 – CHF 13.44 · fair‑value band CHF 2.83 – CHF 4.34 · the CHF 8.26 price screens above the CHF 3.30 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
medmix AG (MEDX) currently trades at CHF 8.26, while our model-based Fair Value estimate is CHF 3.30 — implying the stock looks roughly 60.0% overvalued today. We read business quality at 94/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, medmix AG generated revenue of CHF 448M at a net margin of 1.4%. Revenue declined 8.3% year over year. It earns a return on equity of 1.6%. Net debt stands at CHF 286M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs. It also produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in construction, transportation, electronics, infrastructure, and general industrial sectors; and micro-brushes and applicators for eyes, eyelashes, lips, and facial make-up. The company offers it…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
medmix AG reported revenue of CHF 448M in FY2025 versus CHF 457M in FY2021, a compound −0.5%/yr. Reported net income was CHF 6.4M in FY2025, compounding −38.2%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GE Vernova Inc GEV | $1,035 | $131.95 | -87% |
| SIEGY SIEGY | $155.06 | $89.54 | -42% |
| SMAWF SMAWF | $307.12 | $176.28 | -43% |
| SMNS SMNS | C$31.76 | C$22.85 | -28% |
| SIE SIE | €279.00 | €140.38 | -50% |
| Schneider Electric S.E. SBGSF | $334.00 | $148.44 | -56% |
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is medmix AG (MEDX) undervalued?
What is the fair value of MEDX?
What is the quality score of MEDX?
What is the revenue of medmix AG (MEDX)?
What is the net profit margin of MEDX?
Does medmix AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.